Search
Bazedoxifene
go.drugbank.com/drugs/DB06401ApprovedInvestigationalIt is approved in the European Union (marketed in Italy and Spain) and Japan as monotherapy. … the prevention of postmenopausal osteoporosis in women.
Neisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen
go.drugbank.com/drugs/DB10285ApprovedInvestigationalIt is contained in the suspension of Trumenba, which is a vaccine is composed of two recombinant lipidated factor H binding protein (fHBP) variants from N. meningitidis serogroup B, one from fHBP subfamily
Mixtures: TRUMENBA SUSPENSION FOR INJECTION IN SINGLE-DOSE PRE-FILLED SYRINGE 0.5MLCaplacizumab
go.drugbank.com/drugs/DB06081ApprovedInvestigationalCaplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression … [A174634]In December 2025, the FDA expanded this indication to include pediatric patients aged 12 years and older with aTTP, in the same combination regimen.[L54958,L54963]
Amiloride
go.drugbank.com/drugs/DB00594ApprovedInvestigationalAmiloride is used in conjunction with diuretics to spare potassium loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705) … This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct.
Synonyms: N-amidino-3,5-diamino-6-chloropyrazinecarboxamide, 3,5-diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamideBamlanivimab
go.drugbank.com/drugs/DB15718ApprovedInvestigationalit in collaboration with Eli Lilly and Company. … [L15316, L15321] Under the EUA granted in February 2021, bamlanivimab is used in combination with [etesevimab] to treat mild to moderate COVID-19 in adults and pediatric patients who are at high risk
Mobocertinib
go.drugbank.com/drugs/DB16390ApprovedInvestigationalWithdrawn[A238828] Mobocertinib appears to be an effective means of treating this otherwise treatment-resistant NSCLC, exerting an inhibitory effect on _EGFR_ exon 20 insertion mutant variants at concentrations … It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the _EGFR_ gene,[L38368] which are typically associated with a poorer prognosis (
Fostamatinib
go.drugbank.com/drugs/DB12010ApprovedInvestigationalIt was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, L52150]. Fostamatinib has also been granted orphan drug status by the FDA [L2644]. … Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK
Maralixibat
go.drugbank.com/drugs/DB16226ApprovedInvestigationalwith Alagille syndrome:[L43547] it was granted marketing authorization in Europe on 13 December 2022. … [A239249] Maralixibat represents the first FDA-approved treatment for cholestatic pruritus in patients with Alagille syndrome. It was granted FDA approval on 29 September 2021.
Asenapine
go.drugbank.com/drugs/DB06216ApprovedInvestigationalIt is also for severe post-traumatic stress disorder nightmares in soldiers as an off-label use. FDA approved on August 13, 2009.
Buformin
go.drugbank.com/drugs/DB04830ApprovedWithdrawnIt was withdrawn from the market in most countries due to a high risk of causing lactic acidosis. … Buformin is an anti-diabetic drug of the biguanide class, chemically related to metformin and phenformin.
Categories: Drugs Used in Diabetes